BIOMAT Database Logo BIOMAT Database Logo

Mycophenolate mofetil in cyclosporine-associated nephrotoxicity. 1998

D Ducloux, and V Fournier, and C Bresson-Vautrin, and J M Rebibou, and Y Saint-Hillier, and J M Chalopin
Department of Nephrology and Renal Transplantation, CHU Saint Jacques, Besançon, France.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009173 Mycophenolic Acid Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION. Cellcept,Mycophenolate Mofetil,Mycophenolate Mofetil Hydrochloride,Mycophenolate Sodium,Mycophenolic Acid Morpholinoethyl Ester,Myfortic,RS 61443,RS-61443,Sodium Mycophenolate,Mofetil Hydrochloride, Mycophenolate,Mofetil, Mycophenolate,Mycophenolate, Sodium,RS61443
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D016030 Kidney Transplantation The transference of a kidney from one human or animal to another. Grafting, Kidney,Renal Transplantation,Transplantation, Kidney,Transplantation, Renal,Kidney Grafting,Kidney Transplantations,Renal Transplantations,Transplantations, Kidney,Transplantations, Renal
D016572 Cyclosporine A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed). Cyclosporin A,Ciclosporin,CsA-Neoral,CyA-NOF,Cyclosporin,Cyclosporine A,Neoral,OL 27-400,Sandimmun,Sandimmun Neoral,Sandimmune,CsA Neoral,CsANeoral,CyA NOF,OL 27 400,OL 27400

Related Publications

D Ducloux, and V Fournier, and C Bresson-Vautrin, and J M Rebibou, and Y Saint-Hillier, and J M Chalopin
Use of mycophenolate mofetil in patients with chronic cyclosporine nephrotoxicity.
June 1998, Transplantation proceedings,
D Ducloux, and V Fournier, and C Bresson-Vautrin, and J M Rebibou, and Y Saint-Hillier, and J M Chalopin
Mycophenolate mofetil substitution for cyclosporine-dependent myasthenia gravis and nephrotoxicity.
January 2007, Internal medicine journal,
D Ducloux, and V Fournier, and C Bresson-Vautrin, and J M Rebibou, and Y Saint-Hillier, and J M Chalopin
Mycophenolate mofetil overlap in liver transplant recipients with chronic cyclosporine nephrotoxicity.
September 1999, Transplantation proceedings,
D Ducloux, and V Fournier, and C Bresson-Vautrin, and J M Rebibou, and Y Saint-Hillier, and J M Chalopin
Cyclosporine withdrawal and mycophenolate mofetil treatment effects on the progression of chronic cyclosporine nephrotoxicity.
July 2002, Kidney international,
D Ducloux, and V Fournier, and C Bresson-Vautrin, and J M Rebibou, and Y Saint-Hillier, and J M Chalopin
Reversal of chronic cyclosporine nephrotoxicity after heart transplantation-potential role of mycophenolate mofetil.
September 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation,
D Ducloux, and V Fournier, and C Bresson-Vautrin, and J M Rebibou, and Y Saint-Hillier, and J M Chalopin
Mycophenolate mofetil ameliorates arteriolopathy and decreases transforming growth factor-beta1 in chronic cyclosporine nephrotoxicity.
December 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
D Ducloux, and V Fournier, and C Bresson-Vautrin, and J M Rebibou, and Y Saint-Hillier, and J M Chalopin
Effect of adding Mycophenolate mofetil in paediatric renal transplant recipients with chronical cyclosporine nephrotoxicity.
January 2000, Transplant international : official journal of the European Society for Organ Transplantation,
D Ducloux, and V Fournier, and C Bresson-Vautrin, and J M Rebibou, and Y Saint-Hillier, and J M Chalopin
Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine.
November 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society,
D Ducloux, and V Fournier, and C Bresson-Vautrin, and J M Rebibou, and Y Saint-Hillier, and J M Chalopin
Tacrolimus/mycophenolate mofetil vs cyclosporine/mycophenolate mofetil: comparison of mycophenolate acid trough levels and coronary vasomotor function.
February 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation,
D Ducloux, and V Fournier, and C Bresson-Vautrin, and J M Rebibou, and Y Saint-Hillier, and J M Chalopin
Mycophenolate mofetil and cyclosporine therapy in membranous nephropathy.
May 2003, Seminars in nephrology,
Copied contents to your clipboard!